BACK TO RESEARCH REVIEWS

EmailFacebookTwitterLinkedIn

Authors G Jackson, S Arver, I Banks and VJ Stecher

Review Date Feb 2010

Citation Annals of Internal Medicine 2010;152:568-577

 

Background

There is a growing problem in counterfeit medications around the world, particularly in developing countries. Phosphodiesterase type 5 inhibitors (PDE5is), oral treatments for erectile dysfunction (ED), are contributing to the rapid growth of this market due to the popularity with men with ED of obtaining medication over the internet. There are various reasons for this including the high cost of the drugs and the sensitivity around the problem of ED.

A recent article in the New England Journal of Medicine highlighted the dangers of counterfeit medication, reporting an outbreak of hypoglycaemia (including 4 deaths) in Singapore traced to contamination of counterfeit ED medications with a powerful diabetes drug. Moreover, counterfeiters are becoming increasingly sophisticated and the drugs they produce more difficult to distinguish from their genuine counterparts.

 

Aim

To document the extent of the problem and the dangers associated with counterfeit ED medications.

 

Methods

The authors reviewed the literature concerning counterfeit medication, particularly PED5is, using multiple sources including published articles, government and organisational websites and legal journals.

 

Results

Millions of counterfeit PDE5is are seized yearly and account for the bulk of all counterfeit pharmaceutical product seizures. It has been estimated that up to 2.5 million men in Europe could be exposed to illicit sildenafil (a particular PDE5i), suggesting that there may be as many illegal as legal users of sildenafil. Analysis of the contents of counterfeit PDE5is shows inconsistent doses of active pharmaceutical ingredients (from 0% to > 200% of labelled dose), contaminants (including talcum powder, commercial paint and printer ink) and alternative ingredients that are potentially hazardous. In one analysis, only 10.1% of samples were within 10% of the labelled tablet strength.

Estimates place the proportion of counterfeit medications sold over the Internet from 44% to 90%. Of men who purchase prescription-only medication for ED without a prescription, 67% do so using the Internet. Counterfeit PDE5is pose direct risks to health, including serious illness or death, accidental overdose, drug-drug interactions and incorrect or no guidance regarding contraindications. There are also indirect risks associated with bypassing the medical system. A study showed that more than 30% of men reported no healthcare interaction when purchasing ED medications. Because > 65% actually had ED, these men missed an opportunity for evaluation of comorbidities (e.g. diabetes and hypertension).

 

Conclusion

Globally, increased obstacles for counterfeiters are necessary to combat pharmaceutical counterfeiting, including fines and penalties. The worldwide nature of the counterfeit problem requires proper coordination between countries to ensure adequate enforcement.

Physicians who treat ED need to inform patients of the dangers of ordering PDE5is via the Internet.

 

Points to Note
  1. The counterfeit medication market is an increasing problem and PDE5is are contributing to this burgeoning market.
  2. Many men use the internet to buy ED medications to lower costs and to avoid potentially embarrassing discussions with medical professional.
  3. There are direct and indirect risks to health from counterfeit PDE5is including lack of effectiveness due to inadequate dosing, adverse events from contamination with other drugs or substances, and missed opportunities for proper diagnosis of ED and evaluation of comorbidities.
  4. Doctors involved in treating men with ED should discuss with their patients the risks associated with ordering PED5is over the internet.
  5. Medical professionals can help men to distinguish legitimate from illegitimate sources of PDE5is.
  6. The authors have associations with legitimate drug companies that produce PDE5is. It is in the companies’ interest to reduce counterfeiting and they are devoting considerable resources to dealing with the problem and bringing it to our attention

 

Website: http://www.ncbi.nlm.nih.gov/pubmed/20439575